Please assess the completion status of the following clinical trial:

Trial Title: Non-inferiority Trial on Monoclonal Antibodies in COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 50 years~* Informed consent by the subject or legally authorized representative~* Laboratory-confirmed SARS-CoV-2 infection, as determined by antigen or nucleic acid identification in any specimen, within 4 days of eligibility assessment~* Peripheral oxygen saturation ≥ 94% on room air and not requiring supplemental oxygen~* Onset of symptoms within 4 days of eligibility assessment. Onset time of symptoms is defined as the time when the patient experienced the presence of at least one of the following SARS-CoV-2 infection-associated symptoms for the first time \[4\]: cough, nasal congestion, sore throat, feeling hot or feverish, myalgia, fatigue, headache, anosmia/ageusia, nausea, vomiting, and/or diarrhoea~Exclusion Criteria:~* Previously or currently hospitalized or requiring hospitalization~* Respiratory distress with respiratory rate ≥ 25 breaths/min~* Heart rate ≥ 125 beats per minute~* Peripheral oxygen saturation ≤ 93% on room air at sea level~* Known allergies to any of the components used in the formulation of the trial drugs~* Hemodynamic instability requiring use of pressors within 24 hours of randomization~* Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that could potentially lead to hospitalization within 30 days~* Any co-morbidity requiring surgery within 7 days or that is considered life-threatening within 90 days~* History of positive SARS-CoV-2 test prior to 4 days of the eligibility assessment~* Previous treatment with a SARS-CoV-2 specific monoclonal antibody~* History of convalescent COVID-19 plasma treatment~* Participation in a clinical study involving an investigational intervention within the last 30 days~* Pregnancy or breast feeding~* Investigator site personnel directly affiliated with this study~* Sexually active women of childbearing potential or sexually active men who are unwilling to practice effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after the last dose~* Inability to participate to the study follow-up

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bamlanivimab Etesevimab (Type: EXPERIMENTAL): Bamlanivimab 700 mg + Etesevimab 1400 mg administered in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour
- Sotrovimab (Type: EXPERIMENTAL): Sotrovimab 500 mg administered in 100 mL prefilled 0.9% sodium chloride injection infusion solution over 1/2 hour
- Casirivimab Imdevimab (Type: ACTIVE_COMPARATOR): Casirivimab 600 mg + Imdevimab 600 mg administered in 250 mL prefilled 0.9% sodium chloride injection infusion solution over one hour

Based on this trial design, predict the completion outcome and termination type (if applicable).